Does Rallies track congressional trades in NVO?

Yes. Rallies tracks politician and congressional stock disclosures for NVO, including reported purchases, sales, dates, owners, and trade amounts when available.

Is NVO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for NVO. It does not provide personalized investment advice.

NVO (Novo-Nordisk A/S) Stock Analysis - Politician Trades

Novo-Nordisk A/S (NVO) is a publicly traded Healthcare sector company. As of May 20, 2026, NVO trades at $45.12 with a market cap of $196.24B and a P/E ratio of 0.00. NVO moved +1.77% today. Year to date, NVO is -15.48%; over the trailing twelve months it is -33.93%. Its 52-week range spans $35.12 to $125.62. Analyst consensus is neutral with an average price target of $43.00. Rallies surfaces NVO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Which politicians traded NVO stock?

Recent politician trading activity in NVO includes disclosures from Marjorie Taylor Greene, Lisa McClain, Marjorie Taylor Greene, Marjorie Taylor Greene, and Lisa McClain. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.

NVO Key Metrics

Key financial metrics for NVO
Metric	Value
Price	$45.12
Market Cap	$196.24B
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	1.22%
52-Week High	$125.62
52-Week Low	$35.12
Volume	9.29M
Avg Volume	0
Revenue (TTM)	$0
Net Income	$0
Gross Margin	0.00%

Congressional Trades in NVO

Marjorie Taylor Greene purchase NVO on Oct 15, 2025 (amount: $15.00K).
Lisa McClain purchase NVO on Sep 11, 2025 (amount: $15.00K) for Spouse.
Marjorie Taylor Greene purchase NVO on Aug 28, 2025 (amount: $15.00K).
Marjorie Taylor Greene purchase NVO on Aug 19, 2025 (amount: $50.00K).
Lisa McClain sale NVO on Aug 4, 2025 (amount: $15.00K) for Spouse.

Latest NVO News

Novo Nordisk Plans International Wegovy Launch After 2M US Prescriptions — May 18, 2026
High-Dose Wegovy Delivers 28% Weight Loss as Q1 Uptake Accelerates — May 13, 2026
Novo Nordisk GLP-1 Sales Hit DKK63.25B; Citigroup Lifts Target to DKK290 — May 12, 2026
Novo Nordisk’s High-Dose Wegovy Yields 28% Weight Loss, Hims & Hers Partnership — May 12, 2026
Novo Nordisk Transfers Parkinson’s Program to $60M-Funded AI Startup — May 11, 2026

NVO Analyst Consensus

8 analysts cover NVO: 0 strong buy, 1 buy, 7 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $43.00.

Common questions about NVO

Which politicians traded NVO stock?: Recent politician trading activity in NVO includes disclosures from Marjorie Taylor Greene, Lisa McClain, Marjorie Taylor Greene, Marjorie Taylor Greene, and Lisa McClain. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in NVO?: Yes. Rallies tracks politician and congressional stock disclosures for NVO, including reported purchases, sales, dates, owners, and trade amounts when available.
Is NVO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for NVO. It does not provide personalized investment advice.